The Evolving Arena of Ovarian Cancer Maintenance Therapy

被引：1
作者：
Markman, Maurie [1 ,2 ]
机构：
[1] Canc Treatment Ctr Amer, 1331 East Wyoming Ave, Philadelphia, PA 19124 USA
[2] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA
来源：
ONCOLOGY | 2019年 / 97卷 / 04期
关键词：
Ovarian cancer; Maintenance therapy; Bevacizumab; PARP inhibitors; DOUBLE-BLIND; EPITHELIAL OVARIAN; ONCOLOGY-GROUP; OPEN-LABEL; PLATINUM; BEVACIZUMAB; RECURRENT; TRIAL; CHEMOTHERAPY; PACLITAXEL;
D O I：
10.1159/000501618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Based on the results of several phase 3 randomized trials, "maintenance therapy" (prolonged treatment after an initial response to cytotoxic chemotherapy) has assumed a critical role in the routine care of advanced epithelial ovarian cancer. While earlier data had provided support for this therapeutic concept in disease management (e.g., multiple cycles of single-agent paclitaxel following a clinical complete response to a platinum/paclitaxel regimen), more recent data has revealed both the efficacy and safety of the anti-angiogenesis agent, bevacizumab, and several PARP inhibitors when employed in this clinical setting. (C) 2019 S. Karger AG, Basel
引用
收藏
页码：202 / 205
页数：4
相关论文
共 16 条
  • [1] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Aghajanian, Carol
    Blank, Stephanie V.
    Goff, Barbara A.
    Judson, Patricia L.
    Teneriello, Michael G.
    Husain, Amreen
    Sovak, Mika A.
    Yi, Jing
    Nycum, Lawrence R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2039 - 2045
  • [2] A PROSPECTIVE RANDOMIZED COMPARISON OF 6 AND 12 CYCLES OF CYCLOPHOSPHAMIDE, ADRIAMYCIN, AND CISPLATIN IN ADVANCED EPITHELIAL OVARIAN-CANCER - A DANISH OVARIAN STUDY-GROUP TRIAL (DACOVA)
    BERTELSEN, K
    JAKOBSEN, A
    STROYER, I
    NIELSEN, K
    SANDBERG, E
    ANDERSEN, JE
    AHRONS, S
    NYLAND, M
    PEDERSEN, PH
    LARSEN, G
    RASMUSSEN, P
    KIAER, H
    BICHEL, P
    JACOBSEN, M
    HOLUND, B
    [J]. GYNECOLOGIC ONCOLOGY, 1993, 49 (01) : 30 - 36
  • [3] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
    Burger, Robert A.
    Brady, Mark F.
    Bookman, Michael A.
    Fleming, Gini F.
    Monk, Bradley J.
    Huang, Helen
    Mannel, Robert S.
    Homesley, Howard D.
    Fowler, Jeffrey
    Greer, Benjamin E.
    Boente, Matthew
    Birrer, Michael J.
    Liang, Sharon X.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) : 2473 - 2483
  • [4] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
    Coleman, Robert L.
    Oza, Amit M.
    Lorusso, Domenico
    Aghajanian, Carol
    Oaknin, Ana
    Dean, Andrew
    Colombo, Nicoletta
    Weberpals, Johanne, I
    Clamp, Andrew
    Scambia, Giovanni
    Leary, Alexandra
    Holloway, Robert W.
    Amenedo Gancedo, Margarita
    Fong, Peter C.
    Goh, Jeffrey C.
    O'Malley, David M.
    Armstrong, Deborah K.
    Garcia-Donas, Jesus
    Swisher, Elizabeth M.
    Floquet, Anne
    Konecny, Gottfried E.
    McNeish, lain A.
    Scott, Clare L.
    Cameron, Terri
    Maloney, Lara
    Isaacson, Jeff
    Goble, Sandra
    Grace, Caroline
    Harding, Thomas C.
    Raponi, Mitch
    Sun, James
    Lin, Kevin K.
    Giordano, Heidi
    Ledermann, Jonathan A.
    [J]. LANCET, 2017, 390 (10106) : 1949 - 1961
  • [5] Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
    Coleman, Robert L.
    Brady, Mark F.
    Herzog, Thomas J.
    Sabbatini, Paul
    Armstrong, Deborah K.
    Walker, Joan L.
    Kim, Byoung-Gie
    Fujiwara, Keiichi
    Tewari, Krishnansu S.
    O'Malley, David M.
    Davidson, Susan A.
    Rubin, Stephen C.
    DiSilvestro, Paul
    Basen-Engquist, Karen
    Huang, Helen
    Chan, John K.
    Spirtos, Nick M.
    Ashfaq, Raheela
    Mannel, Robert S.
    [J]. LANCET ONCOLOGY, 2017, 18 (06) : 779 - 791
  • [6] RANDOMIZED PROSPECTIVE TRIAL OF 5 VERSUS 10 CYCLES OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN IN ADVANCED OVARIAN-CARCINOMA
    HAKES, TB
    CHALAS, E
    HOSKINS, WJ
    JONES, WB
    MARKMAN, M
    RUBIN, SC
    CHAPMAN, D
    ALMADRONES, L
    LEWIS, JL
    [J]. GYNECOLOGIC ONCOLOGY, 1992, 45 (03) : 284 - 289
  • [7] Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
    Ledermann, Jonathan
    Harter, Philipp
    Gourley, Charlie
    Friedlander, Michael
    Vergote, Ignace
    Rustin, Gordon
    Scott, Clare
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela
    Macpherson, Euan
    Watkins, Claire
    Carmichael, James
    Matulonis, Ursula
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15) : 1382 - 1392
  • [8] PARP inhibitors: Synthetic lethality in the clinic
    Lord, Christopher J.
    Ashworth, Alan
    [J]. SCIENCE, 2017, 355 (6330) : 1152 - 1158
  • [9] Follow-up of memorial Sloan-Kettering cancer center patients treated on National Cancer Institute treatment referral center protocol 9103: Paclitaxel in refractory ovarian cancer
    Markman, M
    Hakes, T
    Barakat, R
    Curtin, J
    Almadrones, L
    Hoskins, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 796 - 799
  • [10] Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial
    Markman, M
    Liu, PY
    Wilczynski, S
    Monk, B
    Copeland, LJ
    Alvarez, RD
    Jiang, C
    Alberts, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) : 2460 - 2465
12